Followers | 44 |
Posts | 3243 |
Boards Moderated | 2 |
Alias Born | 01/18/2016 |
Thursday, February 22, 2024 1:27:20 PM
Coya’s VP of Operations and Patient Advocacy, Daniel Barvin, had the opportunity to shed light on the world of his empowering patient story and Coya’s fight against neurodegenerative diseases in Houston for the Reel Abilities, UP Abilities event.
All my postings are verified and approved by my dog.
Recent COYA News
- Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer • Business Wire • 11/01/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2024 08:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 12:00:55 PM
- Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain) • Business Wire • 10/29/2024 10:30:00 AM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/28/2024 09:00:30 PM
- Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease • Business Wire • 10/28/2024 12:00:00 PM
- Coya Therapeutics Announces Closing of $10.0 Million Private Placement • Business Wire • 10/23/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/22/2024 01:08:01 PM
- Coya Therapeutics Announces $10.0 Million Private Placement • Business Wire • 10/22/2024 01:00:00 PM
- Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 • Business Wire • 10/08/2024 01:15:00 PM
- Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference • Business Wire • 09/24/2024 12:15:00 PM
- Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease • Business Wire • 09/16/2024 12:15:00 PM
- Coya Therapeutics to Present at Upcoming Healthcare Conferences • Business Wire • 09/03/2024 12:15:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 07:56:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 01:10:00 PM
- Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 • Business Wire • 08/19/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 12:13:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:04:26 PM
- Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results • Business Wire • 08/12/2024 12:00:00 PM
- Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid • Business Wire • 08/02/2024 12:15:00 PM
- Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists • Business Wire • 07/31/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 10:10:01 AM
- Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic • Business Wire • 06/20/2024 12:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 09:01:07 PM
- Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology • Business Wire • 06/11/2024 12:15:00 PM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM